Pacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results

MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Third Quarter 2020 Financial Results Total revenue for the third quarter of 2020 was $19.1 million, compared with $21.9 million for the same period of 2019. Instrument... Read more

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment... Read more

Structuring Semiconductor Materials with Atomic Precision

Researchers use helium ion microscopy to engineer atomic defects in molybdenum disulfide (MoS2) Prof. Alexander Holleitner, Dr. Christoph Kastl, and Elmar Mitterreiter, who performed the HIM-lithography at the atomistic limit. Prof. Alexander Holleitner and his group head the Center of Nanotechnology and Nanomaterials of the Walter Schottky Institute (WSI) of TUM. As the name implies,... Read more

QIAGEN expands its existing Epigenomic offering in the United States with Sample to Insight solution for Hi-C NGS analysis

Hilden, Germany, and Germantown, Maryland, October 29, 2020 – QIAGEN today announced a non-exclusive agreement with Phase Genomics, Inc. to license specific patents to sell its EpiTect Hi-C kits in the United States. Through this agreement, QIAGEN now has access to support chromatin research in the largest research market in the world. Chromatin conformation research,... Read more

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020

SAN DIEGO–(BUSINESS WIRE)—- $ILMN #ILMN–Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior... Read more